« 2011 Drug Approvals Are Up: We Rule, Right? |
| Chinese Research: Not Quite the Juggernaut? »
July 29, 2011
Merck Announces More Big Cutbacks
This is not good, not good at all: Merck is out this morning with earnings, and they're saying that they're going to cut at least 12% of their work force over the next four years. That's up to 13,000 jobs, and the word is that 35 to 40% of those cuts will be in the US.
This is after they'd already done a fair amount of restructuring after the Schering-Plough deal. And it makes a person wonder: was that deal such a good idea? Has Merck really gotten their money's worth out of it, or have they just brought on a big upheaval that could have been avoided? Going down the list of Schering-Plough assets that were advanced at the time of the acquisition, and the shape that they're in now, I really don't think it looks like something that just had to be done. Hindsight?
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- Did Pfizer Cut Back Some of Its Best Compounds?
- Don't Optimize Your Plasma Protein Binding
- Fluorinated Fingerprinting
- One of Those Days
- ChemDraw Days
- Incomprehensible Drug Prices? Think Again.
- Proteins Grazing Against Proteins
- Sulfates, And What They Can Make